Navigation Links
Concord Medical to Report Second Quarter 2013 Financial Results on Aug 12, 2013
Date:8/1/2013

BEIJING, Aug 1, 2013 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical", or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced the Company will release its financial results for the second quarter of 2013 after the market closes, at 6:00 pm EDT on Aug 12, 2013.

Management will hold a conference call to discuss the results the following day, at 8:00 am EDT on Aug 13, 2013 (8:00 pm in Beijing/Hong Kong on Aug 13, 2013).

The dial-in details for the live conference call are as follows:

U.S. Toll Free: 1 866 519 4004
U.K. Toll Free: 08082346646
International: 65 67239381
China Toll Free: 4006208038 / 8008190121
Hong Kong Toll Free: 800930346
Passcode: CCM

A replay of the conference call may be accessed by phone at the following numbers for 7 days:

U.S. Toll Free: 18554525696
International: +61 2 8199 0299
Conference ID: 26409831

Additionally, a live and archived webcast of the conference call will be available on the Investor Relations section of the Company's website at: http://ir.concordmedical.com/.

About Concord Medical

Concord Medical Services Holdings Limited operates the largest network of radiotherapy and diagnostic imaging centers in China, measured by revenues and the number of centers in operation. As of June 30, 2013, the Company operated a network of 140 centers with 77 hospital partners that spanned 53 cities and 24 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, Concord Medical provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. For more information, please see http://ir.concordmedical.com.

Investor and Media Contacts:

Concord Medical Services

Mr. Adam J. Sun
adam.sun@concordmedical.com
(+86) 10 5957-5266

Mr. Ting Jia
ting.jia@concordmedical.com
(+86) 10 5957-5270

ICR

In China:
Ms. Rene Jiang
Rene.Jiang@icrinc.com
(+86) 10 6583 7521

In the United States:
Mr. William Zima
William.Zima@icrinc.com
1-203-682-8233


'/>"/>
SOURCE Concord Medical Services Holdings Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Concord Medical Announces Launch of Mobile Health Application
2. Concord Medical Reports First Quarter 2013 Financial Results
3. Concord Medical Announces the Signing of US$50 Million IFC Loan Agreement
4. Concord Medical to Report First Quarter 2013 Financial Results on May 21, 2013
5. Concord Medical Files 2012 Annual Report on Form 20-F with U.S. Securities and Exchange Commission
6. Concord Medical Reports Fourth Quarter and Full Year 2012 Financial Results
7. Concord Medical to Report Fourth Quarter and Full Year 2012 Financial Results on March 20, 2013
8. DDS Lab Announces Strategic Alliance with United Concordia
9. Concord Medical Acquires Ownership Interest in MD Anderson Cancer Center Proton Therapy Center
10. Concord Medical to Hold Annual General Meeting on December 22, 2012
11. Concord Medical Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... LifeScienceIndustryResearch.com adds "Ulcerative Colitis ... with comprehensive information on the therapeutic development for ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Ulcerative Colitis ...
(Date:5/27/2016)... -- Hutchison China MediTech (Chi-Med) (HCM) ... highly lucrative global oncology and immunology markets. HCM ... or best-in-class tyrosine kinase inhibitor (TKI) drugs, some ... HCM,s profitable Chinese healthcare business continues to benefit ... of the mid-to-late-stage pipeline during 2016-17 (including US ...
(Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
Breaking Medicine Technology:
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... With ... intervention to walk, the demand for a sustainable product to aid in the rehabilitation ... and aid in the recovery of individuals with hemiplegia due to stroke. , Ekso ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response ... many who are unaware of the plight of aphasia. In collaboration with the ... “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively unknown, ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... 2016 , ... Cabot Corporation, Pfizer, and 3M are responsible ... documents and SEC filings. A jury has returned a verdict of $32.8 ... Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 million in ...
Breaking Medicine News(10 mins):